Phase 1/2a Study of BLB-201 Vaccine in RSV Seronegative and Seropositive Infants and Children
Status:
Not yet recruiting
Trial end date:
2024-05-23
Target enrollment:
Participant gender:
Summary
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety,
tolerability and immunogenicity of two ascending doses (10^6 PFU and 10^7 PFU) of intranasal
BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (6-24 months of
age) and children (18-59 months of age) who may or may not have had prior respiratory
syncytial virus (RSV) infection.